NO975585L - C-4' modifiserte adenosin-kinase inhibitorer - Google Patents
C-4' modifiserte adenosin-kinase inhibitorerInfo
- Publication number
- NO975585L NO975585L NO975585A NO975585A NO975585L NO 975585 L NO975585 L NO 975585L NO 975585 A NO975585 A NO 975585A NO 975585 A NO975585 A NO 975585A NO 975585 L NO975585 L NO 975585L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- adenosine kinase
- modified adenosine
- adenosine
- substituents
- Prior art date
Links
- 239000003121 adenosine kinase inhibitor Substances 0.000 title abstract 4
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical class Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003843 furanosyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/486,161 US5674998A (en) | 1989-09-15 | 1995-06-07 | C-4' modified adenosine kinase inhibitors |
| PCT/US1996/010404 WO1996040705A1 (fr) | 1995-06-07 | 1996-06-07 | Inhibiteurs de l'adenosine kinase modifies en c-4' |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO975585D0 NO975585D0 (no) | 1997-12-03 |
| NO975585L true NO975585L (no) | 1998-02-05 |
Family
ID=23930844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO975585A NO975585L (no) | 1995-06-07 | 1997-12-03 | C-4' modifiserte adenosin-kinase inhibitorer |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5674998A (fr) |
| EP (1) | EP0832091B1 (fr) |
| JP (1) | JPH11507387A (fr) |
| KR (1) | KR19990022740A (fr) |
| CN (1) | CN1190401A (fr) |
| AP (1) | AP9701165A0 (fr) |
| AT (1) | ATE257841T1 (fr) |
| AU (1) | AU6178396A (fr) |
| BG (1) | BG102163A (fr) |
| BR (1) | BR9609013A (fr) |
| CA (1) | CA2220642A1 (fr) |
| CZ (1) | CZ392797A3 (fr) |
| DE (1) | DE69631330T2 (fr) |
| EA (1) | EA199800009A1 (fr) |
| HU (1) | HUP9802193A3 (fr) |
| IL (1) | IL122335A0 (fr) |
| IS (1) | IS4621A (fr) |
| MX (1) | MX9709859A (fr) |
| NO (1) | NO975585L (fr) |
| OA (1) | OA10639A (fr) |
| PL (1) | PL323904A1 (fr) |
| SK (1) | SK166097A3 (fr) |
| TR (1) | TR199701539T1 (fr) |
| WO (1) | WO1996040705A1 (fr) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0682027B1 (fr) * | 1994-05-03 | 1997-10-15 | Novartis AG | Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative |
| DE69619114T2 (de) * | 1995-07-06 | 2002-10-02 | Novartis Ag, Basel | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| YU25500A (sh) * | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| KR20020092904A (ko) * | 1999-08-27 | 2002-12-12 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 피롤로[2,3-ｄ]피리미딘 누클레오사이드 유사체 |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| JP2003509428A (ja) | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
| HK1048439A1 (zh) * | 1999-12-16 | 2003-04-04 | Alcon, Inc. | 用於治疗视神经及视网膜损伤之腺激酶抑制剂 |
| WO2001058920A2 (fr) * | 2000-02-10 | 2001-08-16 | Mitsui Chemicals, Inc. | Procede de production selective d'un anomere derive d'un sucre 1-phosphoryle |
| US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
| US7414036B2 (en) * | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| BRPI0400869B8 (pt) * | 2004-03-02 | 2021-05-25 | Univ Estadual Campinas Unicamp | novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases |
| WO2006068760A2 (fr) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Pyrazolopyrimidines anti-inflammatoires |
| EP1848718B1 (fr) | 2005-02-04 | 2012-08-01 | Millennium Pharmaceuticals, Inc. | Inhibiteurs d'enzymes d'activation e1 |
| BRPI0615157A2 (pt) * | 2005-08-12 | 2016-09-13 | Merck & Co Inc | composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto |
| MY171289A (en) | 2006-02-02 | 2019-10-07 | Millennium Pharm Inc | Inhibitors of e1 activating enzymes |
| GB2453058A (en) | 2006-04-04 | 2009-03-25 | Univ California | Kinase antagonists |
| WO2009046448A1 (fr) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Entités chimiques et leurs utilisations thérapeutiques |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CN104926815B (zh) * | 2008-01-04 | 2017-11-03 | 英特利凯恩有限责任公司 | 某些化学实体、组合物和方法 |
| WO2009114874A2 (fr) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés |
| JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| WO2010006072A2 (fr) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Modulateurs de mtor et leurs utilisations |
| WO2010006086A2 (fr) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Inhibiteurs de kinases et procédés d'utilisation |
| EP2346508B1 (fr) | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Inhibiteurs hétérocycliques de kinases |
| JP5819195B2 (ja) | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| NZ596470A (en) | 2009-05-14 | 2014-04-30 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate |
| WO2011005860A2 (fr) * | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Mimétiques de 5' phosphate |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| WO2011146882A1 (fr) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Composés chimiques, compositions et procédés pour modulation de kinases |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| WO2013012915A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composés hétérocycliques et leurs utilisations |
| CA2842190A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
| CN103998442B (zh) | 2011-08-29 | 2016-09-14 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| EP2751112B1 (fr) | 2011-09-02 | 2019-10-09 | The Regents of The University of California | Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci |
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP3255049A1 (fr) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2 |
| KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
| HRP20181367T4 (hr) | 2012-11-01 | 2021-11-26 | Infinity Pharmaceuticals, Inc. | Liječenje raka korištenjem modulatora izoforme pi3 kinaze |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| WO2015160975A2 (fr) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| EP3212201B1 (fr) | 2014-10-28 | 2022-10-19 | BCI Pharma | Inhibiteurs de la kinase nucléoside |
| JP2018523665A (ja) | 2015-08-06 | 2018-08-23 | キメリックス インコーポレイテッド | 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| CA3028718A1 (fr) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Polytherapies |
| EP3684771B1 (fr) | 2017-09-21 | 2024-11-27 | Chimerix, Inc. | Formes morphiques de 4-amino-7-(3,4-dihydroxy-5-(hydroxyméthyle)tétrahydrofurane-2-yl)-2-méthyle-7 h-pyrrolo(2,3-d)pyrimidine-5-carboxamide et leurs utilisations |
| WO2021023888A1 (fr) | 2019-08-08 | 2021-02-11 | B.C.I. Pharma | Dérivés d'isoquinoline utilisés comme inhibiteurs de protéine kinase |
| JP2023508978A (ja) * | 2019-12-23 | 2023-03-06 | サンフォード バーナム プレビス メディカル ディスカバリー インスティテュート | エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ１）モジュレーター及びその使用 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4644394A2 (fr) | 2020-02-18 | 2025-11-05 | Gilead Sciences, Inc. | Composes antiviraux |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| KR102639275B1 (ko) * | 2021-06-08 | 2024-02-21 | 퓨쳐메디신 주식회사 | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 |
| WO2023023527A1 (fr) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Composés phospholipidiques et leurs procédés de production et d'utilisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455420A (en) * | 1983-01-13 | 1984-06-19 | Hoffmann-La Roche Inc. | 4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine |
| DE3712735A1 (de) * | 1987-04-15 | 1988-11-10 | Boehringer Mannheim Gmbh | Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| AU665184B2 (en) * | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
| FI933303L (fi) * | 1991-01-23 | 1993-08-31 | Gensia Inc | Adenosinkinasinhibitorer |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| AU673055B2 (en) * | 1993-02-03 | 1996-10-24 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1995
- 1995-06-07 US US08/486,161 patent/US5674998A/en not_active Expired - Fee Related
-
1996
- 1996-06-07 KR KR1019970709182A patent/KR19990022740A/ko not_active Withdrawn
- 1996-06-07 IL IL12233596A patent/IL122335A0/xx unknown
- 1996-06-07 PL PL96323904A patent/PL323904A1/xx unknown
- 1996-06-07 HU HU9802193A patent/HUP9802193A3/hu unknown
- 1996-06-07 WO PCT/US1996/010404 patent/WO1996040705A1/fr not_active Ceased
- 1996-06-07 SK SK1660-97A patent/SK166097A3/sk unknown
- 1996-06-07 BR BR9609013-8A patent/BR9609013A/pt unknown
- 1996-06-07 EP EP96919442A patent/EP0832091B1/fr not_active Expired - Lifetime
- 1996-06-07 AT AT96919442T patent/ATE257841T1/de not_active IP Right Cessation
- 1996-06-07 TR TR97/01539T patent/TR199701539T1/xx unknown
- 1996-06-07 EA EA199800009A patent/EA199800009A1/ru unknown
- 1996-06-07 CA CA002220642A patent/CA2220642A1/fr not_active Abandoned
- 1996-06-07 CZ CZ973927A patent/CZ392797A3/cs unknown
- 1996-06-07 DE DE69631330T patent/DE69631330T2/de not_active Expired - Fee Related
- 1996-06-07 CN CN96195383A patent/CN1190401A/zh active Pending
- 1996-06-07 AP APAP/P/1997/001165A patent/AP9701165A0/en unknown
- 1996-06-07 JP JP9502290A patent/JPH11507387A/ja not_active Ceased
- 1996-06-07 AU AU61783/96A patent/AU6178396A/en not_active Abandoned
-
1997
- 1997-11-26 IS IS4621A patent/IS4621A/is unknown
- 1997-12-03 OA OA70150A patent/OA10639A/en unknown
- 1997-12-03 NO NO975585A patent/NO975585L/no unknown
- 1997-12-08 MX MX9709859A patent/MX9709859A/es unknown
-
1998
- 1998-01-07 BG BG102163A patent/BG102163A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE257841T1 (de) | 2004-01-15 |
| DE69631330T2 (de) | 2004-10-28 |
| WO1996040705A1 (fr) | 1996-12-19 |
| MX9709859A (es) | 1998-08-30 |
| CA2220642A1 (fr) | 1996-12-19 |
| US5674998A (en) | 1997-10-07 |
| TR199701539T1 (xx) | 1998-04-21 |
| EP0832091A1 (fr) | 1998-04-01 |
| BR9609013A (pt) | 1999-12-14 |
| AU6178396A (en) | 1996-12-30 |
| AP9701165A0 (en) | 1998-01-31 |
| NO975585D0 (no) | 1997-12-03 |
| CN1190401A (zh) | 1998-08-12 |
| EA199800009A1 (ru) | 1998-06-25 |
| EP0832091B1 (fr) | 2004-01-14 |
| IL122335A0 (en) | 1998-04-05 |
| IS4621A (is) | 1997-11-26 |
| BG102163A (en) | 1998-10-30 |
| OA10639A (en) | 2002-09-17 |
| HUP9802193A3 (en) | 1999-10-28 |
| KR19990022740A (ko) | 1999-03-25 |
| DE69631330D1 (de) | 2004-02-19 |
| HUP9802193A2 (hu) | 1999-05-28 |
| JPH11507387A (ja) | 1999-06-29 |
| CZ392797A3 (cs) | 1999-04-14 |
| SK166097A3 (en) | 1999-06-11 |
| PL323904A1 (en) | 1998-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO975585L (no) | C-4' modifiserte adenosin-kinase inhibitorer | |
| ATE296309T1 (de) | Wasserlösliche adenosin kinase inhibitoren | |
| ATE282628T1 (de) | Oral aktive adenosinkinase-inhibitoren | |
| Hao et al. | Factors determining the activity of 2', 3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. | |
| Carson et al. | Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase (s) | |
| Balzarini et al. | 2', 3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. | |
| Brink et al. | Metabolism and distribution of 9-β-D-arabinofuranosyladenine in mouse tissues | |
| EP0653439A3 (fr) | Oligonucléotides stabilisés et leur utilisation. | |
| NO932289L (no) | 2'-deoksy-2',2'-difluor(4-substituerte pyrimidin)nukleosider med antiviralog anticanceraktivitet og mellomprodukter | |
| Uberti et al. | The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation | |
| CA2419399A1 (fr) | Derives de nucleosides | |
| Sanghvi et al. | Antitumor and antiviral activity of synthetic. alpha.-and. beta.-ribonucleosides of certain substituted pyrimido [5, 4-d] pyrimidines: a new synthetic strategy for exocyclic aminonucleosides | |
| DK468288D0 (da) | Antivirale forbindelser | |
| Piper et al. | Biochemical basis for the differential sensitivity of human T-and B-lymphocyte lines to 5-fluorouracil | |
| EP0334361A3 (fr) | Dérivés acétyléniques, cyano et alléniques d'aristéromycine/adénosine | |
| IE831386L (en) | Pharmaceutical compositions based on xylosides and lyxosides¹of purine and pyrimidine bases | |
| DK0720604T3 (da) | Konformationelt låste nukleosidanaloger | |
| Leoutsakos et al. | The effect of adenosine and its analogues on cyclic AMP changes and histamine secretion from rat peritoneal mast cells stimulated by various ligands | |
| Montgomery | The design of chemotherapeutic agents | |
| BR0016162A (pt) | Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos | |
| Törnevik et al. | 2', 3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine. | |
| Gosselin et al. | New unnatural L-nucleoside enantiomers: from their stereospecific synthesis to their biological activities | |
| Diamantstein et al. | Regulation of DNA synthesis by guanosine-5′-diphosphate, cyclic guanosine-3′, 5′-monophosphate, and cyclic adenosine-3′, 5′-monophosphate in mouse lymphoid cells | |
| Miura et al. | The Antitumor Mechanism of 1‐(2‐Deoxy‐2‐fluoro‐4‐thio‐β‐D‐arabinofuranosyl)‐cytosine: Effects of Its Triphosphate on Mammalian DNA Polymerases | |
| EP0665016A4 (fr) | Analeptique des fonctions cardiaques. |